Diagnostic Center | July 27, 2022
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Orion to receive an upfront payment of USD 290 million
Cellutions BioStorage is a comprehensive biomaterial storage and logistics company with a vision to leverage advanced technologies to serve biopharmaceutical companies
The Bill aims to amend and consolidate the law relating to the import, manufacture, distribution and sale of drugs, medical devices and cosmetics
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
The new program includes upstream and downstream process development and large-scale GMP production.
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Subscribe To Our Newsletter & Stay Updated
